This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
It recently celebrated a big win in China, but legal issues at home could threaten the stock in the short term. These 10 stocks could mint the next wave of millionaires › B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK) , reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership following the sale stands at 22,933 shares, according to the SEC Form 4 filing Metric Value Shares sold Transaction value ~$323,650 Post-transaction shares Post-transaction value (direct ownership) ~$1,485,800 Transaction value based on SEC Form 4 reported price ($64.73); post-transaction value based on Nov. 19, 2025 market close ($64.79). How significant was this sale relative to B. Lynne Parshall's remaining direct holdings? The disposition represented 17.9% of direct ownership immediately prior to the transaction, with post-sale holdings at 22,933 shares. How does this transaction compare to
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
- Cytokinetics (NASDAQ:CYTK) was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.MarketBeat
- Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic CardiomyopathyGlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- 12/8/25 - Form 4
- CYTK's page on the SEC website